Srikanth Naramala

TL;DR: The impact of COVID-19 infection on chronic kidney disease (CKD) and renal transplant patients is discussed in the manuscript and remdesivir has received emergency use authorization by the Food and Drug Administration in the USA for use in patients hospitalized with CO VID-19.

TL;DR: The case of a 66-year-old woman who was diagnosed with influenza A and COVID-19 co-infection is described, and active and supportive treatment is the mainstay of treatment for others.

TL;DR: The epidemiology and etiology of acute kidney injury, management of acute kidneys injury including renal replacement therapy options (both hemodialysis and peritoneal dialysis) for inpatient floor, as well as intensive care unit settings, and measures required to limit the spread of infection are discussed.

TL;DR: A systematic and protocol-driven approach is needed to contain this disease, which was declared as a global pandemic on March 11, 2020, by the WHO.

TL;DR: This review article seeks to collate and provide a summary of treatment strategies for COVID-19 patients with a variable degree of illness and discuss pharmacologic and other therapies intended to be used either as experimental medicine/therapy or as part of supportive care in complicated cases of CO VID-19.